Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Combined analysis of restriction fragment length polymorphism of regions of genes coding for rRNA (ribotyping) and esterase electrophoretic typing was used to document neonatal acquisition of Escherichia coli in twins. Our study shows vertical mother-to-infant transmission of one strain of E. coli to one twin and the development of neonatal septicemia with a distinct nonvirulent carboxylesterase type B1 E. coli strain for the other twin.
 ...
PMID:Molecular epidemiology unravels the complexity of neonatal Escherichia coli acquisition in twins. 162 51

One hundred Escherichia coli isolates from human septicemia were characterized with respect to O serogroups 1, 2, 4, 6, 7, 8, 15, 18, 75 and 78, alpha-hemolysin, carboxylesterase B typing, cytotoxic necrotizing factor, F165 and CS31A fimbrial antigens, aerobactin production, colicins, and antibiotic sensitivity. A factorial analysis of correspondence and chi 2 tests indicated that most of E. coli isolates belonging to the studied O serogroups were positive for the virulence factors or markers alpha-haemolysin, carboxylesterase B2 type, cytotoxic necrotizing factor, F165 fimbrial antigen and were antibiotic-sensitive (Group I). These characteristics differentiated them from E. coli isolates from other O serogroups which were generally antibiotic resistant and negative for the cited virulence factors and markers (Group II). Aerobactin and colicin production did not differentiate the two E. coli groups. E. coli O serogroups 4 and 6 were highly represented in group I and were responsible for most of the differences between the two groups.
 ...
PMID:Factors and markers of virulence in Escherichia coli from human septicemia. 222 63

Pyrrolothiazole 4 is a potent antagonist of platelet activating factor-mediated effects in a variety of in vitro and in vivo assays. Despite its positive activity in models of inflammation and septic shock, 4 lacks the aqueous solubility necessary for intravenous administration. This deficit was overcome by conversion of 4 to water-soluble pyridinium prodrugs. A two-step procedure was used to prepare a series of N-(acyloxyalkyl)pyridinium salts, all of which exhibited aqueous solubility of greater than 20 mg/mL. The rate of conversion of these prodrugs to 4 was faster in human plasma than in pH 7 aqueous buffer. This rate difference was shown to be due to serum enzymes since the conversion in plasma was significantly slower in the presence of a serine esterase inhibitor. A strong correlation between prodrug structure and buffer/plasma half-life was established. The N-(acetyloxymethyl)pyridinium prodrug 11 (ABT-299) is currently undergoing clinical evaluation for the treatment of sepsis.
 ...
PMID:N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist. 779 95